Drug Profile
Research programme: aggrecanase inhibitors - AstraZeneca/Celltech
Latest Information Update: 18 Sep 2007
Price :
$50
*
At a glance
- Originator AstraZeneca; Celltech Group
- Class
- Mechanism of Action Aggrecanase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 11 Sep 2002 Preclinical trials in Osteoarthritis in United Kingdom (unspecified route)
- 02 May 2001 Celltech Chiroscience Discovery is now called Celltech R&D
- 02 Feb 2000 Medeva has been merged into Celltech Chiroscience, which is now called Celltech Group